Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, produces significantly greater reductions in HbA1c and body weight compared to selective GLP-1 receptor agonists (semaglutide) and basal insulin in patients with type 2 diabetes.
If you have Type 2 Diabetes, Tirzepatide offers the highest level of blood sugar and weight loss control currently available in injectable medications, surpassing other popular GLP-1 drugs. It works by mimicking two natural gut hormones. The key to success is starting with a very low dose and increasing it slowly every few weeks to minimize stomach upset, which is the main reason people stop taking these drugs.
Tirzepatide was significantly more effective in reducing HbA1c and body weight than the selective GLP-1 RA semaglutide (1.0 mg per week), and titrated basal insulin.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS 1-5) with large patient numbers and rigorous design.
Source
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck et al. · Cardiovascular Diabetology · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →